dostęp otwarty
Diagnostyka i terapia bezsenności w praktyce ogólnolekarskiej. Część II: Terapia bezsenności.
- Katedra i Klinika Medycyny Ratunkowej, Gdański Uniwersytet Medyczy, ul. Smoluchowskiego 17, 80-212 Gdansk
- Centrum Medyczne LuxMed, Ul. Pomorska 96, Gdańsk
dostęp otwarty
Streszczenie
Streszczenie
Słowa kluczowe
bezsenność, terapia poznawcza, higiena snu, benzodiazepiny, leki przeciwderpesyjne, melatonina
Tytuł
Diagnostyka i terapia bezsenności w praktyce ogólnolekarskiej. Część II: Terapia bezsenności.
Czasopismo
Numer
Strony
12-18
Opublikowany online
2019-02-05
Wyświetlenia strony
563
Wyświetlenia/pobrania artykułu
709
Rekord bibliograficzny
Forum Medycyny Rodzinnej 2019;13(1):12-18.
Słowa kluczowe
bezsenność
terapia poznawcza
higiena snu
benzodiazepiny
leki przeciwderpesyjne
melatonina
Autorzy
Mariusz Siemiński
Łukasz Skorupa
Karolina Wiśniewska-Skorupa
- Avidan AY, Neubauer DN. Chronic Insomnia Disorder. Continuum (Minneap Minn). 2017; 23(4, Sleep Neurology): 1064–1092.
- Riemann D, Baglioni C, Bassetti C, et al. European guideline for the diagnosis and treatment of insomnia. J Sleep Res. 2017; 26(6): 675–700.
- Spielman AJ, Caruso LS, Glovinsky PB. A behavioral perspective on insomnia treatment. Psychiatr Clin North Am. 1987; 10(4): 541–553.
- Miller CB, Espie CA, Epstein DR, et al. The evidence base of sleep restriction therapy for treating insomnia disorder. Sleep Med Rev. 2014; 18(5): 415–424.
- Falloon K, Elley CR, Fernando A, et al. Simplified sleep restriction for insomnia in general practice: a randomised controlled trial. Br J Gen Pract. 2015; 65(637): e508–e515.
- Harris J, Lack L, Kemp K, et al. A randomized controlled trial of intensive sleep retraining (ISR): a brief conditioning treatment for chronic insomnia. Sleep. 2012; 35(1): 49–60.
- Trauer JM, Qian MY, Doyle JS, et al. Cognitive Behavioral Therapy for Chronic Insomnia: A Systematic Review and Meta-analysis. Ann Intern Med. 2015; 163(3): 191–204.
- Sateia MJ, Buysse DJ, Krystal AD, et al. Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline. J Clin Sleep Med. 2017; 13(2): 307–349.
- Roth T, Rogowski R, Hull S, et al. Efficacy and Safety of Doxepin 1 mg, 3 mg, and 6 mg in Adults with Primary Insomnia. Sleep. 2007; 30(11): 1555–1561.
- Krystal AD, Lankford A, Durrence HH, et al. Efficacy and safety of doxepin 3 and 6 mg in a 35-day sleep laboratory trial in adults with chronic primary insomnia. Sleep. 2011; 34(10): 1433–1442.
- Lankford A, Rogowski R, Essink B, et al. Efficacy and safety of doxepin 6 mg in a four-week outpatient trial of elderly adults with chronic primary insomnia. Sleep Med. 2012; 13(2): 133–138.
- Yeung WF, Chung KF, Yung KP, et al. Doxepin for insomnia: a systematic review of randomized placebo-controlled trials. Sleep Med Rev. 2015; 19: 75–83.
- Walsh J, Erman M, Erwin CW, et al. Subjective hypnotic efficacy of trazodone and zolpidem in DSMIII-R primary insomnia. Human Psychopharmacology: Clinical and Experimental. 1998; 13(3): 191–198, doi: 10.1002/(sici)1099-1077(199804)13:3<191::aid-hup972>3.0.co;2-x.
- Wichniak A, Wierzbicka A, Sobańska A, et al. The effectiveness of treatment with trazodone in patients with primary insomnia without and with prior history of hypnotics use. Pol Merkur Lekarski. 2007; 23(133): 41–46.
- Roth AJ, McCall WV, Liguori A. Cognitive, psychomotor and polysomnographic effects of trazodone in primary insomniacs. J Sleep Res. 2011; 20(4): 552–558.
- Yi XY, Ni SF, Ghadami MR, et al. Trazodone for the treatment of insomnia: a meta-analysis of randomized placebo-controlled trials. Sleep Med. 2018; 45: 25–32.
- Brzezinski A, Vangel MG, Wurtman RJ, et al. Effects of exogenous melatonin on sleep: a meta-analysis. Sleep Med Rev. 2005; 9(1): 41–50.
- Auld F, Maschauer EL, Morrison I, et al. Evidence for the efficacy of melatonin in the treatment of primary adult sleep disorders. Sleep Med Rev. 2017; 34: 10–22.
- Mayer G, Wang-Weigand S, Roth-Schechter B, et al. Efficacy and safety of 6-month nightly ramelteon administration in adults with chronic primary insomnia. Sleep. 2009; 32(3): 351–360.
- Roth T, Seiden D, Sainati S, et al. Effects of ramelteon on patient-reported sleep latency in older adults with chronic insomnia. Sleep Med. 2006; 7(4): 312–318.
- Mini LJ, Wang-Weigand S, Zhang J. Self-reported efficacy and tolerability of ramelteon 8 mg in older adults experiencing severe sleep-onset difficulty. Am J Geriatr Pharmacother. 2007; 5(3): 177–184.
- Sieminski M, Szypenbejl J, Partinen E. Orexins, Sleep, and Blood Pressure. Curr Hypertens Rep. 2018; 20(9): 79.
- Michelson D, Snyder E, Paradis E, et al. Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2014; 13(5): 461–471.
- Herring WJ, Connor KM, Ivgy-May N, et al. Suvorexant in Patients With Insomnia: Results From Two 3-Month Randomized Controlled Clinical Trials. Biol Psychiatry. 2016; 79(2): 136–148.
- Born S, Gauvin DV, Mukherjee S, et al. Preclinical assessment of the abuse potential of the orexin receptor antagonist, suvorexant. Regul Toxicol Pharmacol. 2017; 86: 181–192.